Sunil Bhandari Hull & East Yorkshire Hospitals NHS Trust United Kingdom

Time	Session

14:15 15:15	Late Breaking Clinical Trials Session Liz Lightstone Chairperson Imperial College London and Hammersmith HospitalUnited Kingdom Sydney Tang Chairperson The University of Hong KongHong Kong, China STOP-ACEi Study Sunil Bhandari Speaker Hull & East Yorkshire Hospitals NHS Trust United Kingdom Q and A DETERMINANTS OF THE EFFECTS OF SGLT2i ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNEY TRIAL Natalie Staplin Free Communication University of OxfordUnited Kingdom Q and A SPARSENTAN REDUCES PROTEINURIA IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN): INTERIM RESULTS OF THE PROTECT STUDY Muh Geot Wong Speaker University of SydneyAustralia Q and A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF ARTESUNATE IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS Jianwen YU Free Communication The First Affiliated Hospital of Sun Yat-sen UniversityChina Q and A Plenary Halls 2 & 3

Time

Session

14:15

15:15

Late Breaking Clinical Trials Session

Liz Lightstone Chairperson Imperial College London and Hammersmith HospitalUnited Kingdom

Sydney Tang Chairperson The University of Hong KongHong Kong, China

STOP-ACEi Study

Sunil Bhandari Speaker Hull & East Yorkshire Hospitals NHS Trust United Kingdom
Q and A
DETERMINANTS OF THE EFFECTS OF SGLT2i ON PROGRESSION OF CKD: FURTHER RESULTS FROM THE EMPA-KIDNEY TRIAL

Natalie Staplin Free Communication University of OxfordUnited Kingdom
Q and A
SPARSENTAN REDUCES PROTEINURIA IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IGAN): INTERIM RESULTS OF THE PROTECT STUDY

Muh Geot Wong Speaker University of SydneyAustralia
Q and A
RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL OF ARTESUNATE IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

Jianwen YU Free Communication The First Affiliated Hospital of Sun Yat-sen UniversityChina
Q and A

Plenary Halls 2 & 3